Literature DB >> 8980179

Kaposi's sarcoma and non-Hodgkin's lymphoma following the diagnosis of AIDS. Multistate AIDS/Cancer Match Study Group.

R J Biggar1, P S Rosenberg, T Coté.   

Abstract

We linked records of 83,434 AIDS cases reported to AIDS registries through 1990 to cancer registry records during times when overlap in registration existed. Of 8,496 Kaposi's-sarcoma (KS) cases meeting enrollment criteria, 1,045 occurred semesters 2 through 4 (6 through 23 months) after another AIDS-defining illness. KS risk in this period after AIDS declined steadily over the 1980s. Adjusting for age, gender, ethnic origin and calendar time period, we found the relative risk (RR) of KS to be 106,000 for homo/bisexual men with AIDS and 13,000 for other men with AIDS. Risk was highest for homo/bisexual men between 30 and 39 years old and among 20- to 29-year-old non-homo/bisexual men. The RR in black men was approximately half that reported in white men among homo-bisexual men and others. Between the second and fourth semester after AIDS, the ratio of RR of KS to that of non-AIDS-related cancers increased 1.5-fold. In a similar analysis, there were 335 non-Hodgkin's lymphoma (NHL) cases in semesters 2 through 4 after AIDS. The overall risk was elevated 283-fold in homo/bisexual men and the RR ratio increased 1.8-fold between semester 2 and 4 after AIDS. In summary, the risk of KS following another AIDS-defining illness is strikingly high, more in white men than in black men, and the risks of KS and, especially, NHL appear to increase with time from AIDS.

Entities:  

Mesh:

Year:  1996        PMID: 8980179     DOI: 10.1002/(SICI)1097-0215(19961211)68:6<754::AID-IJC11>3.0.CO;2-0

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

1.  Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi's sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial.

Authors:  Mary Cianfrocca; Sandra Lee; Jamie Von Roenn; Michelle A Rudek; Bruce J Dezube; Susan E Krown; Joseph A Sparano
Journal:  Cancer Chemother Pharmacol       Date:  2011-01-05       Impact factor: 3.333

2.  Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.

Authors:  Joseph A Sparano; Jeannette Y Lee; Lawrence D Kaplan; Alexandra M Levine; Juan Carlos Ramos; Richard F Ambinder; William Wachsman; David Aboulafia; Ariela Noy; David H Henry; Jamie Von Roenn; Bruce J Dezube; Scot C Remick; Manisha H Shah; Lawrence Leichman; Lee Ratner; Ethel Cesarman; Amy Chadburn; Ronald Mitsuyasu
Journal:  Blood       Date:  2009-12-18       Impact factor: 22.113

3.  Activation of NF-kappaB by the human herpesvirus 8 chemokine receptor ORF74: evidence for a paracrine model of Kaposi's sarcoma pathogenesis.

Authors:  S Pati; M Cavrois; H G Guo; J S Foulke; J Kim; R A Feldman; M Reitz
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

4.  Risk of lymphatic or haematopoietic cancer mortality with occupational exposure to animals or the public.

Authors:  M A Svec; M H Ward; M Dosemeci; H Checkoway; A J De Roos
Journal:  Occup Environ Med       Date:  2005-10       Impact factor: 4.402

5.  A Kaposi's sarcoma-associated herpesviral protein inhibits virus-mediated induction of type I interferon by blocking IRF-7 phosphorylation and nuclear accumulation.

Authors:  Fan Xiu Zhu; Sonya M King; Eric J Smith; David E Levy; Yan Yuan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-09       Impact factor: 11.205

Review 6.  State of the art: gastrointestinal malignancies in the human immunodeficiency virus (HIV) population.

Authors:  Mary Koshy; John Kauh; Clifford Gunthel; Melissa Joyner; Jerome Landry; Charles R Thomas
Journal:  Int J Gastrointest Cancer       Date:  2005

7.  Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial).

Authors:  Marta Epeldegui; Jeannette Y Lee; Anna C Martínez; Daniel P Widney; Larry I Magpantay; Deborah Regidor; Ronald Mitsuyasu; Joseph A Sparano; Richard F Ambinder; Otoniel Martínez-Maza
Journal:  Clin Cancer Res       Date:  2015-09-17       Impact factor: 12.531

8.  Human immunodeficiency virus type 1 Tat accelerates Kaposi sarcoma-associated herpesvirus Kaposin A-mediated tumorigenesis of transformed fibroblasts in vitro as well as in nude and immunocompetent mice.

Authors:  Xiuying Chen; Lin Cheng; Xuemei Jia; Yi Zeng; Shuihong Yao; Zhigang Lv; Di Qin; Xin Fang; Yongliang Lei; Chun Lu
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

Review 9.  Social Inequalities in Palliative Care for Cancer Patients in the United States: A Structured Review.

Authors:  Ronit Elk; Tisha M Felder; Ebru Cayir; Cleo A Samuel
Journal:  Semin Oncol Nurs       Date:  2018-08-23       Impact factor: 2.315

10.  Tumorigenesis by human herpesvirus 8 vGPCR is accelerated by human immunodeficiency virus type 1 Tat.

Authors:  Hong-Guang Guo; Shibani Pati; Mariola Sadowska; Man Charurat; Marvin Reitz
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.